PE20231439A1 - Proteinas f de hmpv estabilizadas por prefusion - Google Patents
Proteinas f de hmpv estabilizadas por prefusionInfo
- Publication number
- PE20231439A1 PE20231439A1 PE2023001803A PE2023001803A PE20231439A1 PE 20231439 A1 PE20231439 A1 PE 20231439A1 PE 2023001803 A PE2023001803 A PE 2023001803A PE 2023001803 A PE2023001803 A PE 2023001803A PE 20231439 A1 PE20231439 A1 PE 20231439A1
- Authority
- PE
- Peru
- Prior art keywords
- modified
- protein
- seq
- metapneumovirus
- prefusion
- Prior art date
Links
- 241000342334 Human metapneumovirus Species 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 241000351643 Metapneumovirus Species 0.000 abstract 4
- 102000035118 modified proteins Human genes 0.000 abstract 4
- 108091005573 modified proteins Proteins 0.000 abstract 4
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000013639 protein trimer Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 239000013638 trimer Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
- C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
- C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
Referido a una proteina modificada que comprende un ectodominio de proteina F de metapneumovirus humano (hMPV) estabilizadas por prefusion, que tiene al menos 90 % de identidad con (i) los aminoacidos 19 a 489 de cualquiera de las SEQ ID NO: 1, 2 y 4 a 7, o (ii) los aminoacidos 19 a 484 de la SEQ ID NO: 3, dicha proteina modificada comprende al menos una mutacion relativa a la secuencia de cualquiera de las SEQ ID NO: 1 a 7, dicha al menos una mutacion comprende una sustitucion en una posicion correspondiente a: K166, N342, A/D185, K188, entre otros. Tambien se refiere un trimero de proteina F de metapneumovirus (MPV) modificado que comprende al menos una subunidad, a una molecula de acido nucleico que comprende una secuencia de nucleotidos que codifica una secuencia de aminoacidos de dicha proteina modificada, una composicion farmaceutica que comprende un vehiculo farmaceuticamente aceptable y (i) la proteina modificada o (ii) el trimero modificado; y su uso en el tratamiento o la prevencion de una infeccion por metapneumovirus (MPV).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063089978P | 2020-10-09 | 2020-10-09 | |
| PCT/US2021/053944 WO2022076669A1 (en) | 2020-10-09 | 2021-10-07 | Prefusion-stabilized hmpv f proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231439A1 true PE20231439A1 (es) | 2023-09-14 |
Family
ID=81125547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023001803A PE20231439A1 (es) | 2020-10-09 | 2021-10-07 | Proteinas f de hmpv estabilizadas por prefusion |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11919927B2 (es) |
| EP (1) | EP4225364A1 (es) |
| JP (1) | JP2023544834A (es) |
| KR (1) | KR20230084201A (es) |
| CN (1) | CN116615235A (es) |
| AU (1) | AU2021357826A1 (es) |
| CA (1) | CA3195015A1 (es) |
| CO (1) | CO2023005373A2 (es) |
| IL (1) | IL301950A (es) |
| MX (1) | MX2023004078A (es) |
| PE (1) | PE20231439A1 (es) |
| WO (1) | WO2022076669A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4243865A1 (en) | 2020-11-13 | 2023-09-20 | Icosavax, Inc. | Protein-based nanoparticle vaccine for metapneumovirus |
| WO2023110618A1 (en) * | 2021-12-16 | 2023-06-22 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion hmpv fusion proteins |
| WO2023217988A1 (en) * | 2022-05-12 | 2023-11-16 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion hmpv fusion proteins |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10017543B2 (en) | 2013-03-13 | 2018-07-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
| US9738689B2 (en) | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
| WO2016103238A1 (en) | 2014-12-24 | 2016-06-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant metapneumovirus f proteins and their use |
| WO2019233842A1 (en) * | 2018-06-08 | 2019-12-12 | F. Hoffmann-La Roche Ag | Peptidic linker with reduced post-translational modification |
| KR20220010478A (ko) | 2019-05-20 | 2022-01-25 | 발네바 에스이 | 기도 감염의 치료 또는 예방용 서브유닛 백신 |
| EP4142785A2 (en) | 2020-04-29 | 2023-03-08 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Recombinant human metapneumovirus f proteins and their use |
| WO2023110618A1 (en) | 2021-12-16 | 2023-06-22 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion hmpv fusion proteins |
-
2021
- 2021-10-07 CA CA3195015A patent/CA3195015A1/en active Pending
- 2021-10-07 KR KR1020237014520A patent/KR20230084201A/ko unknown
- 2021-10-07 AU AU2021357826A patent/AU2021357826A1/en active Pending
- 2021-10-07 IL IL301950A patent/IL301950A/en unknown
- 2021-10-07 PE PE2023001803A patent/PE20231439A1/es unknown
- 2021-10-07 EP EP21878525.1A patent/EP4225364A1/en active Pending
- 2021-10-07 MX MX2023004078A patent/MX2023004078A/es unknown
- 2021-10-07 JP JP2023521506A patent/JP2023544834A/ja active Pending
- 2021-10-07 WO PCT/US2021/053944 patent/WO2022076669A1/en active Application Filing
- 2021-10-07 CN CN202180075353.6A patent/CN116615235A/zh active Pending
-
2023
- 2023-04-06 US US18/296,771 patent/US11919927B2/en active Active
- 2023-04-27 CO CONC2023/0005373A patent/CO2023005373A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11919927B2 (en) | 2024-03-05 |
| KR20230084201A (ko) | 2023-06-12 |
| CN116615235A (zh) | 2023-08-18 |
| EP4225364A1 (en) | 2023-08-16 |
| JP2023544834A (ja) | 2023-10-25 |
| AU2021357826A1 (en) | 2023-05-11 |
| CA3195015A1 (en) | 2022-04-14 |
| CO2023005373A2 (es) | 2023-05-19 |
| WO2022076669A1 (en) | 2022-04-14 |
| MX2023004078A (es) | 2023-05-24 |
| US20230357327A1 (en) | 2023-11-09 |
| AU2021357826A9 (en) | 2023-07-13 |
| IL301950A (en) | 2023-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20231439A1 (es) | Proteinas f de hmpv estabilizadas por prefusion | |
| AR108442A1 (es) | Proteínas de fusión gdf15 y usos de estas | |
| BR112022015628A2 (pt) | Vacina de sars-cov-2 | |
| ES2533874T3 (es) | Armazón proteico | |
| AR058567A1 (es) | Formulaciones de proteinas estables | |
| BRPI0815578B8 (pt) | peptídeos, agentes farmacêuticos compreendendo os mesmos, métodos in vitro para induzir uma célula apresentadora de antígeno, usos dos referidos peptídeos, e vacina | |
| NO20043891L (no) | Anti-A-beta-antistoffer og deres anvendelse | |
| KR960705850A (ko) | 사람 쿠니즈형 프로테아제 저해인자(human kunitz-type protease inhibitors) | |
| ES2721172T3 (es) | Una nueva clase de moléculas terapéuticas a base de proteínas | |
| RU2003104524A (ru) | Masp-2, комплемент-связывающий фермент и его применение | |
| NO20063026L (no) | Antistoffer | |
| BRPI0412799A (pt) | imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura | |
| PE20080397A1 (es) | Proteinas de fusion del receptor de productos finales de glicacion avanzada (ragepor sus sigla en ingles), formulaciones, y metodos de uso de las mismas | |
| BRPI0516176A (pt) | polipeptìdeo, dna, microorganismo, e, processo para produzir l-arginina, l-ornitina ou l-citrulina | |
| PE20190420A1 (es) | Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas | |
| EA200401504A1 (ru) | Слитый белок из числа регуляторных/вспомогательных белков вич | |
| DK1349944T3 (da) | Latensassocieret peptid af TGF-beta til at bibringe farmaceutisk aktive proteiner latens | |
| CO6210831A2 (es) | Nuevas proteinas h5 moleculas de acido nucleico y vectores que las codifican y su uso medicinal | |
| AR035077A1 (es) | Polipeptidos de neublastina variante, proteinas de fusion, acidos nucleicos, vectores, celulas hospedadoras, metodos para producir dichos polipeptidos, dimeros, conjugados, composiciones farmaceuticas y uso de dichos polipeptidos en la preparacion de medicamentos | |
| BR0012919A (pt) | Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv | |
| AR053372A1 (es) | Proteinas inmunologicas de lawsonia intracellularis | |
| DK1079849T3 (da) | Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning | |
| BR112022011975A2 (pt) | Polipeptídeo de interferon-¿2 modificado, polipeptídeo gmop-interferon-¿2 modificado, ácido nucleico, plasmídeo, vetor, linha de célula, método para purificação do polipeptídeo de interferon-¿2 modificado, composição farmacêutica, método para uso de um ou mais dos polipeptídeos de interferon-¿2 modificados e método para tratar uma condição médica em um indivíduo | |
| BR112022026580A2 (pt) | Composições e métodos para induzir uma resposta imune contra coronavírus | |
| RU2014138418A (ru) | Белки пилей и композиции |